INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Market Closed 12-12 16:08:09

85.200

+1.550

+1.85%

High85.950	Low83.000	Vol10.18M
Open84.500	D1 Closing83.650	Amplitude3.53%
Mkt Cap146.63B	Tradable Cap146.63B	Total Shares1.72B
T/O862.46M	T/O Rate0.59%	Tradable Shares1.72B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":85.2,"timestamp":1765526889002,"preClose":83.65,"halted":0,"volume":10184978,"delay":0,"floatShares":1721000000,"shares":1721000000,"eps":-0.06415717304790206,"marketStatus":"Market Closed","change":1.55,"latestTime":"12-12 16:08:09","open":84.5,"high":85.95,"low":83,"amount":862458025,"amplitude":0.035266,"askPrice":85.2,"askSize":19000,"bidPrice":85.1,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.7444112234236198,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":7,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":83.65,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0.4058449028512864,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.2085,"impliedVolPercentile":0.0122},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"1189425921","title":"Hong Kong Stock Short Interest Data as of December 12","url":"https://stock-news.laohu8.com/highlight/detail?id=1189425921","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189425921?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:33","pubTimestamp":1765535584,"startTime":"0","endTime":"0","summary":"As of December 5, the top three stocks with the highest short interest ratios were China Vanke (02202), ZTE (00763), and COSCO SHIP HOLD (01919), with short interest ratios of 20.57%, 17.63%, and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1590","LU0456827905.SGD","SG9999001051.SGD","LU0165289439.USD","LU0348783662.USD","LU0314109678.HKD","03145","LU0348766576.USD","LU1023057109.AUD","LU1880383440.USD","PNGAY","LU1880383366.USD","LU1328277881.USD","LU0049853897.USD","IE0008368742.USD","LU1235295612.USD","02013","LU1642822792.SGD","LU0327786744.USD","LU0890818403.SGD","BK1116","01530","LU0054450605.USD","LU0345780521.USD","01138","02899","BK1224","LU1051768304.USD","LU2097828631.EUR","LU0197773673.USD","LU2097828714.EUR","LU0417516902.SGD","LU0043850808.USD","HK0000306685.HKD","LU0072913022.USD","09995","BK1240","LU0594300179.USD","BK1535","HK0000165453.HKD","LU0051755006.USD","LU0823426480.USD","BK1615","LU1242518857.USD","LU0821914370.USD","LU0588546209.SGD","00763","LU0227179875.USD","IE0034224299.USD","LU1969619763.USD","LU0348783233.USD","BK1586","LU0737861772.HKD","LU0348827113.USD","LU0979878070.USD","BK1104","02318","LU0348825331.USD","LU1282649141.HKD","LU0588545730.USD","SG9999002562.SGD","LU0266512473.USD","LU0163747925.USD","LU0348816934.USD","LU0823426308.USD","LU0455707207.USD","LU0634319403.HKD","BK1593","BK1555","LU0326950275.SGD","BK1506","HK0000306701.USD","BK1589","HK0000320223.HKD","BK1131","LU0072462343.USD","LU1303224171.USD","BK1518","LU2039709279.SGD","LU1188198961.HKD","IE00BZ08YS42.EUR","BK1507","LU0640798160.USD","LU0531971595.HKD","82318","LU2153592121.USD","LU0791591158.USD","LU0417516571.SGD","SG9999001069.SGD","01919","LU1366334651.USD","SG9999001093.SGD","LU2778985437.USD","LU0918141705.HKD","LU1282648689.USD","LU1152091168.USD","BK1205","BK1526","BK1556","BK1170","LU0049112450.USD","LU0359201612.USD","BK1161","LU1044876610.USD","HPAD.SI","LU0106252389.USD","LU2328871848.SGD","LU2476274720.SGD","00839","LU0228659784.USD","BK1166","LU1226287529.USD","IE0003895053.USD","01880","LU0918141887.USD","LU1993786604.SGD","LU0348784397.USD","LU0084288322.USD","LU1769817179.HKD","LU0164880469.USD","LU0164872284.USD","LU0228367735.SGD","LU1051769294.HKD","LU0865486749.SGD","LU0244354667.USD","BK1516","LU0463099449.HKD","LU0345780281.USD","LU0384037296.USD","03750","BK1529","06865","IE00B29SXG58.USD","LU2476274308.USD","LU2348774022.SGD","00863","LU2097828805.USD","LU0588545490.SGD","IE00BF5LJ272.USD","LU0449515922.USD","09863","LU0149721374.USD","BK1612","LU0651947912.USD","LU0254981946.USD","LU1720050803.USD","LU1224709979.USD","LU0329678337.USD","LU0630378692.HKD","02202","LU1481107354.HKD","LU0348767384.USD","LU0328353924.USD","LU0611395673.USD","LU0348814723.USD","LU0370786039.SGD","BK1504","BK1521","IE00BZ08YT58.USD","LU1366334578.USD","BK1109","BK1594","LU0797268264.HKD","LU0067412154.USD","LU1115378108.SGD","LU1794554557.SGD","LU0266512127.USD","BK1617","BK1608","LU0106959298.USD","LU0561508036.HKD","LU2226246903.HKD","SG9999001440.SGD","LU0791590937.USD","BK1103","LU0588545904.SGD","LU1813983027.USD","BK1587","LU1831875114.USD","BK1149","LU1211504680.USD","LU0329678170.USD","LU0572944931.SGD","LU1769817096.USD","LU2242644610.SGD","LU0501845795.SGD","09626","LU0469268626.HKD","BK1169","LU0862451753.SGD","LU1808992512.USD","IE00BVYPNQ40.USD","BK1607","BK1618","02498","LU2399975544.HKD","09880","02382","LU1960683339.HKD","SG9999014674.SGD","LU0348735423.USD","LU1807302812.USD","LU0348788117.USD","LU1981816686.USD","LU0417516738.SGD","IE00BGHQDM52.EUR","LU0871576103.HKD","LU1515016050.SGD","LU2293587155.HKD","BK1141","LU0140636845.USD","LU0196878994.USD","LU0819123356.HKD","LU0762540952.USD","LU0307460666.USD","LU1152091754.HKD","BK1184","LU1105468828.SGD","BK1613","LU2097828474.EUR","LU0540923850.HKD","LU1504937902.USD","LU1251922891.USD","LU1242518931.SGD","PAImain","LU0878004406.USD","LU0819121731.USD","LU0096374516.USD","LU1961090484.USD","BK1574","BK1119","LU0880133367.SGD","SG9999004220.SGD","LU0878005551.USD","IE00BYV24P56.USD","LU1046422090.SGD","LU0708995583.HKD","601318","LU0235996351.USD","BK1095","BK1592","LU2543165471.USD","LU2097828557.USD","LU0762541174.USD","LU0287142896.SGD","00354","BK1610","02228","SG9999003461.SGD","LU0359202008.SGD","01801","LU0828237940.HKD","BK1191","BK1554","LU1044874839.SGD","SG9999002828.SGD","00522","BK1522","LU0488056044.USD","06680","LU0320764599.SGD","BK1550","LU0648948544.HKD","LU0651946864.USD","LU0737861699.HKD","LU2488822045.USD","BK1155","LU0502904849.HKD","BK1619","LU1282649810.SGD","06613","SG9999006597.SGD","BK1505","BK1595","LU0594300419.USD","LU0315179316.USD","BK1546","LU0456854461.SGD","BK1198","SG9999002463.SGD","BK1575","LU1008478684.HKD","LU0605514214.HKD","LU0762542818.HKD","LU1282649067.USD","LU1719994722.HKD","BK1183","LU1044875133.USD","LU0831093199.SGD","BK1179","01072","LU1048588211.SGD","BK1588","LU0650527681.SGD","HK0000320264.USD","LU0274383008.USD","LU0197773160.USD","BK1614","LU0828237510.HKD","LU0039217434.USD","LU0886674414.USD","LU0630378429.USD","LU0359201885.HKD","LU0048580855.USD","LU1048596156.SGD","BK1544","LU0061477393.USD","LU0181495838.USD","01276","BK1228","LU0856984785.SGD","LU0164865239.USD","LU0882747503.HKD","IE00BMCWC346.EUR","LU0173614495.USD","LU0315178854.USD","LU0052750758.USD","BK1583","LU1770034418.SGD","IE00BVYPNP33.GBP","000002","IE00BZ08YR35.GBP","LU0348805143.USD","LU0211977185.USD"],"gpt_icon":1},{"id":"2590554083","title":"Innovent Biologics Reports Mazdutide Achieves Significant Weight Loss in Chinese Adolescents with Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2590554083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590554083?lang=en_us&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497619,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the results of a Phase 1b clinical study evaluating mazdutide, a dual GLP-1 and glucagon receptor agonist, in Chinese adolescents with obesity. The study met its primary endpoint, with participants receiving 4 mg and 6 mg doses of mazdutide achieving BMI reductions of 8.78% and 10.99%, and weight reductions of 7.72 kg and 8.65 kg, respectively, over 12 weeks. These outcomes were significantly greater than those observed in the placebo group. Mazdutide also showed favorable safety and tolerability, with no serious adverse events reported. Improvements were noted in multiple metabolic parameters. Based on these results, Innovent Biologics plans to initiate a Phase 3 registration clinical trial in adolescents with obesity or overweight in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2Zl9Bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","LU2097828714.EUR","HK0000165453.HKD","LU2488822045.USD","01801","LU0455707207.USD","LU2097828557.USD","BK1147","LU1969619763.USD","LU2242644610.SGD","LU2097828474.EUR","LU2097828805.USD","LU0502904849.HKD","BK1589","LU2328871848.SGD","01911","LU2097828631.EUR"],"gpt_icon":0},{"id":"2590751547","title":"Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1B Clinical Trial in Chinese Adolescents With Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2590751547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590751547?lang=en_us&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA35K2NB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","LU0455707207.USD","BK1589","LU2097828805.USD","LU2097828631.EUR","LU0502904849.HKD","LU2097828474.EUR","LU1969619763.USD","LU2097828714.EUR","LU2242644610.SGD","LU2328871848.SGD","LU2097828557.USD","HK0000165453.HKD","LU2488822045.USD","BK1161","01801"],"gpt_icon":0},{"id":"2590900583","title":"Innovent Biologics (SEHK:1801): Reconciling a 116x P/E With DCF-Suggested Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2590900583","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590900583?lang=en_us&edition=fundamental","pubTime":"2025-12-10 15:17","pubTimestamp":1765351025,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) has been on traders’ radar after a choppy stretch that includes a slight pullback today but a strong rebound over the past year. This has raised questions about what the market is really pricing in.\nSee our latest analysis for Innovent Biologics.\nDespite the recent 1 week share price return of minus 10.07 percent and a 90 day share price return of minus 15.26 percent, Innovent’s 1 year total shareholder return of 121.23 percent signals that momentum is still...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-reconciling-a-116x-pe-with-dcf-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/innovent-biologics-sehk1801-reconciling-a-116x-pe-with-dcf-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2097828805.USD","01801","BK1161","DCF","BK1583","LU2097828474.EUR","LU2097828714.EUR","LU1969619763.USD","LU0455707207.USD","HK0000165453.HKD","LU2242644610.SGD","BK1589","LU0502904849.HKD","LU2097828557.USD","LU2328871848.SGD","LU2097828631.EUR","LU2488822045.USD"],"gpt_icon":0},{"id":"1195995366","title":"BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1195995366","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195995366?lang=en_us&edition=fundamental","pubTime":"2025-12-10 14:40","pubTimestamp":1765348821,"startTime":"0","endTime":"0","summary":"According to a research report by BOCOM INTL, the firm maintains a leading rating for China's pharmaceutical industry. The National Healthcare Security Administration recently held the \"2025...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","159992","BK1147","LU0348735423.USD","IE00BPRC5H50.USD","06978","LU0455707207.USD","BK1583","01177","LU1961090484.USD","LU1794554557.SGD","09926","BK1515","LU0348767384.USD","LU0540923850.HKD","LU1720050803.USD","LU1969619763.USD","IE00BZ08YS42.EUR","BK1574","LU0359202008.SGD","LU2097828474.EUR","IE00B5MMRT66.SGD","BK1161","LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU2242644610.SGD","IE00BZ08YR35.GBP","LU0348783233.USD","BK1589","01801","LU0348825331.USD","LU1023057109.AUD","LU0348827113.USD","BK1521","LU0348784397.USD","BK1191","LU0359201612.USD","LU0502904849.HKD","LU2328871848.SGD","LU2097828631.EUR","LU2399975544.HKD","LU2476274308.USD","LU2543165471.USD","LU0417516571.SGD","LU0359201885.HKD","03329","LU2097828714.EUR","LU2778985437.USD","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","LU0417516738.SGD","01276"],"gpt_icon":0},{"id":"2590373878","title":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590373878?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:27","pubTimestamp":1765326446,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein  monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 , which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6WJy9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","LU0455707207.USD","LU2328871848.SGD","HK0000165453.HKD","LU2242644610.SGD","01911","BK1147","LU2097828805.USD","LU1969619763.USD","LU2097828631.EUR","BK1161","LU2097828474.EUR","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD","LU2097828714.EUR","01801"],"gpt_icon":0},{"id":"2590827373","title":"Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of Ibi3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2590827373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590827373?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:27","pubTimestamp":1765326420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA9L5N0L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","LU0502904849.HKD","HK0000165453.HKD","LU1969619763.USD","LU2242644610.SGD","LU2097828714.EUR","BK1161","LU2097828557.USD","LU0455707207.USD","LU2097828631.EUR","BK1583","01801","BK1589","LU2097828474.EUR"],"gpt_icon":0},{"id":"1120480059","title":"CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=1120480059","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120480059?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:14","pubTimestamp":1765246458,"startTime":"0","endTime":"0","summary":"CMB International released a research report stating that the 2025 edition of China's basic medical insurance catalog and the first commercial insurance catalog have been announced, continuing to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","01530","IE00BZ08YR35.GBP","LU2328871848.SGD","LU2488822045.USD","SG9999014674.SGD","BK1207","HK0000165453.HKD","BK1583","LU2242644610.SGD","BK1191","IE00BZ08YT58.USD","SG9999004311.SGD","LU1969619763.USD","LU0455707207.USD","LU2097828714.EUR","01801","BK1515","01177","02273","02367","BK1161","LU2097828805.USD","BK1589","LU2097828474.EUR","02268","IE00BZ08YS42.EUR","LU0502904849.HKD","BK1141","BK1593","BK1219","BK1521","LU2097828631.EUR","CXO"],"gpt_icon":0},{"id":"2590362883","title":"Innovent Biologics' PECONDLE Achieves Phase 3 Success for Moderate-to-Severe Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590362883","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590362883?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:00","pubTimestamp":1765238427,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced that its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, PECONDLE , met both primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study. The CLEAR-2 trial was a randomized withdrawal and retreatment study conducted in Chinese participants with moderate-to-severe plaque psoriasis. PECONDLE received market approval from the National Medical Products Administration  in November 2025 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The results of the Phase 3 study have already been announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLcdBYNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2097828557.USD","LU0455707207.USD","LU1969619763.USD","LU2097828714.EUR","01911","LU2097828805.USD","LU2097828474.EUR","BK1589","BK1161","BK1147","LU2242644610.SGD","LU2328871848.SGD","LU2488822045.USD","LU0502904849.HKD","01801","BK1583","LU2097828631.EUR"],"gpt_icon":0},{"id":"2590364007","title":"Innovent Announces Pecondle® (Picankibart Injection) Phase 3 Study (Clear-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590364007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590364007?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:00","pubTimestamp":1765238400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUAC77C7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2242644610.SGD","BK1589","LU2328871848.SGD","LU2097828714.EUR","01801","LU1969619763.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828557.USD","HK0000165453.HKD","LU2488822045.USD","BK1161","LU0455707207.USD","LU0502904849.HKD","BK1583","LU2097828631.EUR"],"gpt_icon":0},{"id":"1119171968","title":"HK Stock Movement | INNOVENT BIO (01801) Plunges Over 6% with Block Trades Worth Over HK$1.2 Billion Pre-Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1119171968","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119171968?lang=en_us&edition=fundamental","pubTime":"2025-12-08 10:06","pubTimestamp":1765159575,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","LU2488822045.USD","BK1589","LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","HK0000165453.HKD","LU0455707207.USD","LU2097828631.EUR","LU2097828805.USD","01801","LU2097828714.EUR","BK1583","LU1969619763.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2589802568","title":"Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802568","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802568?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:03","pubTimestamp":1765155800,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced initial results from the first-in-human Phase 1 clinical trial of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3 for the treatment of relapsed or refractory multiple myeloma. The data were presented in an oral session at the 2025 American Society of Hematology  Annual Meeting. IBI3003 demonstrated favorable tolerability and a manageable safety profile, with encouraging efficacy signals observed, particularly in high-risk patients, including those with extramedullary disease or prior exposure to anti-BCMA and/or anti-GPRC5D therapies. The ongoing Phase 1/2 clinical trial  is evaluating the safety, tolerability, and efficacy of IBI3003 in China and Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL2LlFwX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU0455707207.USD","BK1161","01801","BK1583","01911","BK1589","LU2097828474.EUR","LU2097828805.USD","LU2097828557.USD","LU2242644610.SGD","LU2488822045.USD","LU0502904849.HKD","BK1147","LU1969619763.USD","LU2097828714.EUR","HK0000165453.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2589802557","title":"Ash 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody Ibi3003 in Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802557?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:03","pubTimestamp":1765155783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUAC8YMC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01801","LU2097828557.USD","LU2328871848.SGD","LU2488822045.USD","BK1583","LU0502904849.HKD","LU2097828714.EUR","LU0455707207.USD","HK0000165453.HKD","BK1161","LU1969619763.USD","LU2097828631.EUR","LU2242644610.SGD","BK1589","LU2097828805.USD","LU2097828474.EUR"],"gpt_icon":0},{"id":"1199213902","title":"Hong Kong Stock Short Selling Stats | Dec 8","url":"https://stock-news.laohu8.com/highlight/detail?id=1199213902","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199213902?lang=en_us&edition=fundamental","pubTime":"2025-12-08 08:29","pubTimestamp":1765153749,"startTime":"0","endTime":"0","summary":"The top three stocks by short-selling ratio in the previous trading session were SHK PPT-R (80016), CHINARES BEER-R (80291), and AIA-R (81299), all at 100.00%. The top three stocks by short-selling...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345780521.USD","BK1152","LU0314109678.HKD","LU1568876335.HKD","BK4538","HK0000320264.USD","LU0577902611.USD","HK0000306685.HKD","BK1516","LU0633140727.USD","LU0417516738.SGD","LU1769817096.USD","LU1504937902.USD","LU2488822045.USD","BK1095","MIUmain","LU1044876610.USD","LU0047713382.USD","LU0823413587.USD","80016","LU1224709979.USD","BK1601","LU0791591158.USD","LU1366334578.USD","LU0449515922.USD","BK4503","LU0862451753.SGD","SG9999001093.SGD","LU1102505929.USD","LU2476274308.USD","LU0501845795.SGD","BK1550","LU0106959298.USD","BK4504","LU2097828474.EUR","BK4502","LU0061477393.USD","LU0979878070.USD","LU0886674414.USD","SG9999015952.SGD","LU0266512127.USD","LU2328871848.SGD","IE00B031J352.USD","02318","BIDU","LU0315179316.USD","IE0008369823.USD","LU0320764755.SGD","LU0254981946.USD","LU0266512473.USD","HK0000252160.HKD","LU0868486357.SGD","LU0011963245.USD","IE0034224299.USD","LU0289961442.SGD","LU0630378429.USD","IE00B543WZ88.USD","LU1675838814.USD","LU0163747925.USD","01211","BK1610","LU0541502299.USD","LU0577902298.EUR","BK1506","IE00B3M56506.USD","BK1582","LU0949170772.SGD","LU1720050803.USD","LU0326948709.USD","BK1509","LU0823041008.USD","PNGAY","LU0244354667.USD","LU1794554557.SGD","LU0791590937.USD","LU0819123356.HKD","METmain","LU0289960550.SGD","LU0165289439.USD","81211","LU0594300179.USD","IE00BD6J9T35.USD","LU0345776255.USD","LU0029875118.USD","81299","01579","BK4543","LU0396098781.USD","LU0259732245.USD","LU0577902538.SGD","BK1191","LU1328277881.USD","LU0572940350.SGD","IE00BFMHRM44.USD","BK1598","LU1956131251.USD","LU0196878994.USD","LU1497733631.SGD","LU0819121731.USD","LU1969619763.USD","HXXD.SI","LU0823038988.USD","LU2153592121.USD","LU0878005551.USD","LU1634259557.SGD","LU0589944569.HKD","BK1128","LU0605514214.HKD","PAImain","LU0293314216.USD","LU0516423091.SGD","LU0149721374.USD","LU1497734951.SGD","LU2357125470.USD","LU0588545490.SGD","LU0650527681.SGD","BK1522","LU1807302812.USD","SG9999001689.USD","03690","BK4614","LU0594300419.USD","LU1251922891.USD","LU1642822792.SGD","LU0326950275.SGD","LU1064131003.USD","LU1880383440.USD","LU0502904849.HKD","LU0505663152.USD","00939","LU0531971595.HKD","BK1119","LU2294711713.HKD","LU0828237510.HKD","IE00B0JY6N72.USD","LU0499858602.USD","BK4122","BK1558","LU0865486749.SGD","LU0572939691.SGD","SG9999007991.SGD","LU1719994722.HKD","BK1216","LU2778985437.USD","BK1227","LU1282649067.USD","SG9999002562.SGD","BK1591","LU1981816686.USD","LU0228367735.SGD","LU0516422440.USD","00136","LU0345780281.USD","LU0320764599.SGD","01801","BK1502","09988","BK1594","BK1607","LU0545039389.USD","HPAD.SI","LU0229945570.USD","LU0588546209.SGD","SG9999003461.SGD","LU0540923850.HKD","LU0588545904.SGD","LU0370786039.SGD","BK4505","LU0449509016.USD","LU2152927971.USD","BK4527","HK0000252152.HKD","LU0181495838.USD","LU0456854461.SGD","LU0082770016.USD","LU0577902454.USD","LU0588545730.USD","IE00BYV24P56.USD","LU0164880469.USD","LU0049112450.USD","BK4581","LU1770036033.HKD","LU0543330566.HKD","LU0823414551.USD","BK1547","89888","LU0132412106.USD","LU0210526637.USD","LU0072913022.USD","BK1523","BYDDY","LU0128522157.USD","82318","LU2449936058.SGD","LU2476274720.SGD","SG9999015945.SGD","HK0000320223.HKD","BK4587","LU0611395673.USD","SG9999006597.SGD","BK1198","BK4220","LU0128525689.USD","LU1226287529.USD","LU0509642566.USD","LU2097828557.USD","LU0831093199.SGD","BK4579","LU0648948544.HKD","LU0096374516.USD","LU0553294199.USD","LU0455707207.USD","LU0572944931.SGD","LU0651947912.USD","IE00BGHQDM52.EUR","LU1115378108.SGD","00341","LU1048596156.SGD","LU0516422366.SGD","LU0918141887.USD","BK1539","BK1583","IE00B29SXG58.USD","BK1180","LU0164872284.USD","LU0441854154.USD","01810","LU0211977185.USD","LU0651946864.USD","SG9999002828.SGD","LU0310800965.SGD","LU1282651121.HKD","LU0456827905.SGD","LU1282649141.HKD","LU0228659784.USD","LU1960683339.HKD","SG9999002463.SGD","LU0634319403.HKD","LU2213484517.USD","LU0463099449.HKD","LU1152091754.HKD","LU1861214812.USD","IE00BVYPNP33.GBP","BK1193","LU1515016050.SGD","LU1003077747.HKD","IE00B5MMRT66.SGD","LU0738911758.USD","LU2360107325.USD","BK4554","LU1105468828.SGD","LU1282651048.USD","LU0054450605.USD","SG9999015978.USD","BK1154","03143","LU2045819591.USD","LU1323998911.USD","BK1587","LU0348783662.USD","LU1048588211.SGD","BK1184","HK0000165453.HKD","LU1303224171.USD","IE00BZ08YS42.EUR","BK4585","LU0348735423.USD","81810","SG9999000459.SGD","LU1868838027.USD","LU0762542818.HKD","LU0143863784.USD","LU0543330483.HKD","LU2257852520.SGD","LU0918141705.HKD","IE0032431581.USD","LU0235996351.USD","SG9999006514.SGD","HK0000306701.USD","SG9999013353.USD","BK1544","LU0417516571.SGD","80291","BK4535","LU0516423174.USD","LU0039217434.USD","02899","IE00BVYPNQ40.USD","LU0143863198.USD","LU0762540952.USD","SG9999015986.USD","LU0264606111.USD","LU0175139822.USD","LU2097828631.EUR","BK1521","LU0251144936.SGD","BABA","LU1152091168.USD","LU0593848301.USD","LU1769817179.HKD","LU1008478684.HKD","LU1211504680.USD","LU1868837565.USD","IE00BWDBJ730.SGD","03145","LU0051755006.USD","LU0531970944.HKD","BK4588","LU1046421795.USD","BK4533","LU0873338254.USD","LU2293587155.HKD","SG9999014674.SGD","LU0456846285.SGD","LU0384037296.USD","LU0856984785.SGD","LU0823426308.USD","LU0348783233.USD","LU0633140560.USD","LU1868837722.USD","LU0251143458.SGD","LU0173614495.USD","LU0274383008.USD","BK4534","IE0003895053.USD","LU0084288322.USD","LU0823040885.USD","LU0048597586.USD","LU0348814723.USD","LU2097828805.USD","LU1023057109.AUD","LU0672654166.SGD","LU0499858438.USD","LU0052756011.USD","LU2087589342.USD","LU0169518387.USD","BK1237","LU0106252389.USD","IE00B19Z5X02.USD","BK4607","LU0214875030.USD","LU1064130708.USD","LU0708995583.HKD","LU1051768304.USD","LU2148611432.USD","LU0289739343.SGD","SG9999000327.SGD","LU1224444064.USD","LU0661504455.SGD","BK4526","SG9999004220.SGD","LU1051769294.HKD","BK1575","SG9999001226.SGD","LU2399975544.HKD","LU1102505762.USD","82388","BK4531","LU0052750758.USD","HMTD.SI","LU0762541174.USD","LU0117841782.USD","LU1328615791.USD","LU0882747503.HKD","LU1048484197.HKD","002594","LU1522347837.USD","IE00BPRC5H50.USD","XIACY","BK1540","LU1813983027.USD","LU1282648689.USD","601318","LU0640798160.USD","09888","LU0359202008.SGD","LU0828237940.HKD","LU2249611893.SGD","BK1505","LU0345775950.USD","IE0031814852.USD","BK1589","ALBmain","LU0516422952.EUR","LU1046422090.SGD","LU0054237671.USD","LU0890818403.SGD","IE00B031HY20.USD","IE00BF5LJ272.USD","LU0307460666.USD","LU0197773160.USD","LU0797268264.HKD","LU1961090484.USD","LU0469268626.HKD","LU0488056044.USD","LU0880133367.SGD","LU0327786744.USD","LU0315178854.USD","LU1688375341.USD","03968","LU0359201885.HKD","LU0329678170.USD","LU2242644610.SGD","BK1590","BK1588","LU0348788117.USD","80941","BK1609","BK1142","LU1497733557.USD","LU1044874839.SGD","LU1831875114.USD","LU0048580855.USD","LU1235294995.USD","LU0359201612.USD","LU0328353924.USD","LU0823039010.USD","LU1044875133.USD","LU2348774022.SGD","LU0541501648.USD","LU0823397103.USD","LU1242518931.SGD","LU0823426480.USD","LU2226246903.HKD","LU1282649810.SGD","LU1568876251.USD","LU1993786604.SGD","LU0348805143.USD","LU1770034418.SGD","LU2125910500.SGD","LU0261950983.USD","LU0737861699.HKD","BK1615","LU0630378692.HKD","BK1233","00916","BK1161","BK4558","LU0049853897.USD","BK1231","LU0823414478.USD","SG9999001903.USD","BK1618","LU0348827113.USD","LU0561508036.HKD","LU0197773673.USD","BK4548","LU2506951792.HKD","MPNGY","IE00BZ08YR35.GBP","LU0164865239.USD","LU1823568750.SGD","LU1267930227.SGD","LU2097828714.EUR","TCHmain","LU1242518857.USD","LU0348784397.USD","LU1808992512.USD","LU0577902371.SGD","BK4575","BK1592","80700","LU0828238088.HKD","LU1634259391.SGD","LU1880383366.USD","LU2148510915.USD","LU0511384066.AUD","82331","LU0072462343.USD","LU0348816934.USD","LU1734074674.USD","IE00BQJZWZ67.USD","IE00BMCWC346.EUR","LU0871576103.HKD","LU0140636845.USD","LU0269904917.USD","HYDD.SI","LU0231483743.USD","IE0008368742.USD","LU0878004406.USD","LU0823397285.USD","LU0675040207.SGD","BK4565","BK1604","LU0737861772.HKD","LU0683595622.HKD","LU0431992006.USD","LU0700851271.USD","LU0067412154.USD","IE00BZ08YT58.USD","HK0000500386.USD","BK1577","03692","LU1366334651.USD","LU0417516902.SGD","LU1235295612.USD","LU0821914370.USD","BK4524","LU0329678337.USD","LU0823413660.USD","LU2039709279.SGD","LU0043850808.USD","LU0287142896.SGD","LU0348825331.USD","LU1861219969.SGD","BK1507","LU1188198961.HKD","LU1481107354.HKD","BK1560"],"gpt_icon":1},{"id":"2589871464","title":"Innovent Biologics Wins NRDL Inclusion for Seven Innovative Drugs in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871464","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589871464?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:06","pubTimestamp":1765101984,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9rqL8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0455707207.USD","BK1589","LU2097828805.USD","LU2097828631.EUR","LU0502904849.HKD","LU2097828474.EUR","LU1969619763.USD","LU2097828714.EUR","LU2242644610.SGD","LU2328871848.SGD","LU2097828557.USD","HK0000165453.HKD","LU2488822045.USD","BK1161","01801","BK1147","01911"],"gpt_icon":0},{"id":"2589873869","title":"Innovent Announces Inclusion of Seven Innovative Drugs Including Tyvyt New Indication and Sycume in China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589873869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589873869?lang=en_us&edition=fundamental","pubTime":"2025-12-07 11:40","pubTimestamp":1765078825,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA97Z24L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK1161","LU2488822045.USD","HK0000165453.HKD","BK1589","BK4007","LU2097828557.USD","LU2097828474.EUR","BK1583","LU1969619763.USD","LU2097828631.EUR","LU2097828714.EUR","LU0502904849.HKD","LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"1171727374","title":"INNOVENT BIO (01801) Grants 15,000 Share Options and 148,200 Restricted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1171727374","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171727374?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:36","pubTimestamp":1764938172,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) announced that on December 5, 2025, the company granted 15,000 share options to 3 grantees and 148,200 restricted shares to 29 grantees under the terms of the 2024 Share Scheme, subject to acceptance by the grantees.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","HK0000165453.HKD","LU2097828805.USD","BK1589","BK1161","LU2097828557.USD","LU2097828631.EUR","LU2242644610.SGD","LU0502904849.HKD","01801","LU2328871848.SGD","LU2488822045.USD","LU2097828474.EUR","LU1969619763.USD","BK1583","LU0455707207.USD"],"gpt_icon":0},{"id":"2589869486","title":"Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2589869486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589869486?lang=en_us&edition=fundamental","pubTime":"2025-12-05 14:53","pubTimestamp":1764917620,"startTime":"0","endTime":"0","summary":"Japanese shares closed lower on Friday as investors waited for a U.S. inflation reading that may influence a split Federal Reserve.The Nikkei 225 fell 1.05%, or 536.55 points, to close at 50,491.87.Th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLTW","LU2097828805.USD","LU2242644610.SGD","TMF","LU2097828714.EUR","LU2488822045.USD","US3Y.BOND","BK1161","US6M.BOND","BK1589","01801","US12M.BOND","LU0455707207.USD","US2Y.BOND","US5Y.BOND","US30Y.BOND","LU1969619763.USD","US7Y.BOND","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU0502904849.HKD","BK1583","HK0000165453.HKD","LU2097828557.USD","US10Y.BOND"],"gpt_icon":1},{"id":"1164459392","title":"Analysis of Hong Kong Stock Connect Holdings | December 5","url":"https://stock-news.laohu8.com/highlight/detail?id=1164459392","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164459392?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:32","pubTimestamp":1764894750,"startTime":"0","endTime":"0","summary":"As of December 4, 2025, the top three stocks by Hong Kong Stock Connect ownership ratio were CHINA TELECOM (00728), DYNAGREEN ENV (01330), and HAO TIAN INTL (01341), with holdings of 72.75%, 69.12%,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456827905.SGD","LU1568876251.USD","LU0873338254.USD","LU0165289439.USD","LU0348783662.USD","LU0314109678.HKD","03145","03968","LU0348766576.USD","LU1023057109.AUD","LU1880383440.USD","PNGAY","LU1880383366.USD","LU1328277881.USD","LU0049853897.USD","IE0008368742.USD","SG9999001689.USD","LU0231483743.USD","LU1235295612.USD","LU1642822792.SGD","LU0327786744.USD","LU0890818403.SGD","IE0032431581.USD","LU0054450605.USD","LU0345780521.USD","00981","01138","02899","SG9999007991.SGD","BK1224","LU0251144936.SGD","LU1051768304.USD","BK1523","LU0264606111.USD","BK1576","LU2097828631.EUR","LU2125910500.SGD","BK1564","LU0197773673.USD","LNVGY","LU2097828714.EUR","01635","LU0417516902.SGD","LU0043850808.USD","BK1552","LU0828238088.HKD","HK0000306685.HKD","LU0072913022.USD","BK1240","BK1558","LU0594300179.USD","01798","BK1535","HK0000165453.HKD","LU0051755006.USD","LU0633140560.USD","LU0823426480.USD","BK1615","LU1242518857.USD","LU0821914370.USD","LU0588546209.SGD","01288","01088","00763","IE0034224299.USD","LU1969619763.USD","LU0348783233.USD","IE0008369823.USD","HK0000252160.HKD","LU0737861772.HKD","LU0348827113.USD","LU0979878070.USD","LU0449509016.USD","HK0000252152.HKD","LU1688375341.USD","02238","02318","80883","LU0348825331.USD","BK1140","LU1282649141.HKD","LU0345776255.USD","LU0516422952.EUR","LU0029875118.USD","SG9999002950.SGD","LU0588545730.USD","LU0593848301.USD","SG9999002562.SGD","LU0266512473.USD","HK0000500386.USD","SGXZ86797644.SGD","BK1233","LU0441854154.USD","LU0163747925.USD","00939","BK1193","LU0348816934.USD","00762","LU0823426308.USD","LU0455707207.USD","LU0396098781.USD","LU0634319403.HKD","BK1555","03678","LU0326950275.SGD","BK1506","HK0000306701.USD","BK1589","02628","HK0000320223.HKD","LU0072462343.USD","LU1303224171.USD","LU2039709279.SGD","LU1188198961.HKD","IE00BZ08YS42.EUR","BK1507","LU0640798160.USD","LU0531971595.HKD","82318","LU0868486357.SGD","IE00B031J352.USD","LU0214875030.USD","LU0128522157.USD","LU2153592121.USD","LU1064130708.USD","LU0791591158.USD","BK1221","01456","LU0143863198.USD","LU0417516571.SGD","SG9999001069.SGD","LU1366334651.USD","SGXZ62798434.SGD","SG9999001093.SGD","LU2778985437.USD","LU0918141705.HKD","03143","LU0261950983.USD","LU1282648689.USD","LU1497733631.SGD","LU1152091168.USD","LU1675838814.USD","BK1526","LU2045819591.USD","LU0541501648.USD","LU0049112450.USD","LU0359201612.USD","BK1161","LU1044876610.USD","HPAD.SI","LU0106252389.USD","LU2328871848.SGD","LU2476274720.SGD","LU0228659784.USD","IE00BPRC5H50.USD","BK1166","LU1226288170.HKD","00956","LU1226287529.USD","IE0003895053.USD","IE00B5MMRT66.SGD","LU0918141887.USD","LU1634259557.SGD","LU1993786604.SGD","LU0348784397.USD","IE0031814852.USD","LU0084288322.USD","LU0700851271.USD","LU0577902538.SGD","LU1769817179.HKD","LU0164880469.USD","LU0164872284.USD","LU0228367735.SGD","LU1051769294.HKD","LU0865486749.SGD","LU0244354667.USD","LU0463099449.HKD","LU0054237671.USD","LU0345780281.USD","LU0384037296.USD","LU0516422366.SGD","BK1529","IE00B29SXG58.USD","SG9999012744.USD","02359","LU2476274308.USD","LU0320764755.SGD","LU1064131003.USD","LU2348774022.SGD","LU1323998911.USD","LU2097828805.USD","LU0588545490.SGD","IE00BF5LJ272.USD","LU0449515922.USD","LU0149721374.USD","LU1568876335.HKD","LU0651947912.USD","80992","00728","03690","BK1133","LU0541502299.USD","LU0254981946.USD","06869","LU0456846285.SGD","LU1720050803.USD","LU0310800965.SGD","LU1224709979.USD","BK1538","LU0329678337.USD","LU0630378692.HKD","BK1238","02202","BK1560","LU1481107354.HKD","LU0348767384.USD","LU0683595622.HKD","LU0328353924.USD","LU0611395673.USD","LU1497734951.SGD","09992","LU0348814723.USD","LU0370786039.SGD","SG9999012710.SGD","BK1521","IE00BZ08YT58.USD","LU1366334578.USD","SG9999013353.USD","BK1594","BK1528","LU0797268264.HKD","LU0572940350.SGD","LU0067412154.USD","LU1115378108.SGD","LU1794554557.SGD","LU0266512127.USD","LU0106959298.USD","LU0561508036.HKD","LU2226246903.HKD","LU0791590937.USD","LU0143863784.USD","LU0675040207.SGD","LU0588545904.SGD","LU0572939691.SGD","LU1813983027.USD","BK1163","LU1224444064.USD","LU1868837565.USD","LU1831875114.USD","BK1149","MPNGY","LU1282651048.USD","01776","LU1211504680.USD","00883","IE00B543WZ88.USD","LU0128525689.USD","LU0329678170.USD","LU0572944931.SGD","LU0577902298.EUR","LU1769817096.USD","LU2242644610.SGD","SG9999012728.SGD","01065","LU0501845795.SGD","03958","LU0469268626.HKD","LU0509642566.USD","LU1328615791.USD","LU0862451753.SGD","LU1808992512.USD","LU0259732245.USD","IE00BVYPNQ40.USD","BK1607","LU1634259391.SGD","BK1618","LU1497733557.USD","BK1584","LU1522347837.USD","LU1770036033.HKD","LU0543330566.HKD","LU1102505762.USD","01108","LU2399975544.HKD","09880","00941","BK1178","LU0516423091.SGD","LU1960683339.HKD","BK1536","LU0348735423.USD","SG9999014674.SGD","LU1807302812.USD","LU0348788117.USD","LU1981816686.USD","LU0633140727.USD","BK1154","LU0417516738.SGD","IE00BGHQDM52.EUR","LU0871576103.HKD","LU1226287792.SGD","LU1515016050.SGD","LU2293587155.HKD","BK1141","BK1537","LU0140636845.USD","BK1152","LU0196878994.USD","LU0819123356.HKD","LU0011963245.USD","BK1539","LU1868837722.USD","IE00BWDBJ730.SGD","LU0762540952.USD","BK1591","LU0307460666.USD","01375","BK1105","IE00B19Z5X02.USD","LU1152091754.HKD","BK1184","LU1105468828.SGD","BK1613","LU2097828474.EUR","LU0540923850.HKD","LU1504937902.USD","LU1951186391.HKD","LU1251922891.USD","LU1242518931.SGD","LU0577902371.SGD","LU0048597586.USD","PAImain","LU0878004406.USD","LU0819121731.USD","LU0096374516.USD","IE00B031HY20.USD","LU0326948709.USD","LU1961090484.USD","03033","IE00B0JY6N72.USD","LU0516423174.USD","LU0823038988.USD","LU0577902454.USD","01330","BK1119","LU0880133367.SGD","SG9999004220.SGD","LU0878005551.USD","IE00BYV24P56.USD","BK1147","LU0577902611.USD","LU1046422090.SGD","LU0708995583.HKD","601318","LU1226288253.USD","LU0235996351.USD","BK1592","LU2087589342.USD","LU2543165471.USD","LU2097828557.USD","LU0762541174.USD","LU0132412106.USD","LU0287142896.SGD","LU1282651121.HKD","BK1610","LU0345775950.USD","LU0359202008.SGD","01801","LU0828237940.HKD","LU2213484517.USD","BK1554","LU1044874839.SGD","SG9999002828.SGD","SG9999000459.SGD","LU2148510915.USD","LU0488056044.USD","LU0823041008.USD","LU0543330483.HKD","LU0320764599.SGD","HMTD.SI","BK1550","LU0648948544.HKD","LU0651946864.USD","LU0737861699.HKD","BK1604","LU2488822045.USD","LU0502904849.HKD","LU1282649810.SGD","SG9999012736.USD","01341","SG9999006597.SGD","BK1505","LU0594300419.USD","LU0229945570.USD","LU0315179316.USD","LU0456854461.SGD","BK1198","SG9999002463.SGD","LU0516422440.USD","LU1048484197.HKD","LU0499858602.USD","BK1575","LU0499858438.USD","LU2257852520.SGD","BK1503","LU0269904917.USD","LU1008478684.HKD","LU0605514214.HKD","LU0762542818.HKD","LU1282649067.USD","LU1719994722.HKD","BK1183","LU1044875133.USD","LU0831093199.SGD","LU1102505929.USD","LU1048588211.SGD","LU0823039010.USD","LU0052756011.USD","LU0589944569.HKD","LU1267930227.SGD","LU0650527681.SGD","HK0000320264.USD","LU0197773160.USD","LU0117841782.USD","BK1614","LU0047713382.USD","LU0828237510.HKD","IE00BQJZWZ67.USD","LU0039217434.USD","00992","LU0886674414.USD","LU0630378429.USD","IE00B3M56506.USD","LU0359201885.HKD","LU0210526637.USD","LU2152927971.USD","LU0048580855.USD","LU0823040885.USD","LU1048596156.SGD","BK1544","LU0061477393.USD","LU0181495838.USD","BK1142","LU1868838027.USD","SG9999000327.SGD","LU1226287875.USD","LU0856984785.SGD","LU0164865239.USD","LU0882747503.HKD","IE00BMCWC346.EUR","LU0173614495.USD","BK1231","LU0315178854.USD","LU0431992006.USD","LU0672654166.SGD","LU0052750758.USD","BK1583","LU1770034418.SGD","IE00BVYPNP33.GBP","SG9999001903.USD","LU1734074674.USD","000002","IE00BZ08YR35.GBP","LU0293314216.USD","LU0348805143.USD","LU0211977185.USD"],"gpt_icon":1},{"id":"2589042853","title":"Innovent Biologics and Takeda Launch $11.4 Billion Global Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2589042853","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589042853?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:39","pubTimestamp":1764891541,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has finalized a global strategic partnership with Takeda to accelerate the development and commercialization of next-generation immuno-oncology  and antibody-drug conjugate  therapies. The collaboration includes joint global development and U.S. co-commercialization of IBI363 , global rights outside Greater China for IBI343 , and an exclusive option for Takeda to license global rights to IBI3001  outside Greater China. Takeda will pay Innovent $1.2 billion upfront, including a $100 million equity investment, with total deal value reaching up to $11.4 billion through additional development, sales milestones, and potential royalties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9L5xZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU2097828631.EUR","LU0502904849.HKD","LU2097828474.EUR","LU0455707207.USD","LU2097828714.EUR","BK1589","LU2097828805.USD","LU2242644610.SGD","BK1161","LU2488822045.USD","01911","01801","LU1969619763.USD","BK1147","LU2328871848.SGD","HK0000165453.HKD","LU2097828557.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0739},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.1293},{"period":"6month","weight":0.0558},{"period":"1year","weight":1.2362},{"period":"ytd","weight":1.3279}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.035915}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}